Lexeo Therapeutics

(NASDAQ) LXEO

Current Price$5.50

Market Cap$426.74M

Since IPO (2023)-43%

5 YearN/A

1 Year+104%

1 Month-18%

Lexeo Therapeutics Financials at a Glance

Market Cap

$426.74M

Revenue (TTM)

$0.00

Net Income (TTM)

$87.50M

EPS (TTM)

$-1.45

P/E Ratio

-3.96

Dividend

$0.00

Beta (Volatility)

1.98 (High)

Dividend

$0.00

Beta (Volatility)

1.98 (High)

Price

$5.50

Volume

21,594

Open

$5.83

Price

$5.50

Volume

21,594

Open

$5.83

Previous Close

$5.50

Daily Range

$5.47 - $5.83

52-Week Range

$2.43 - $10.99

Dividend

$0.00

Beta (Volatility)

1.98 (High)

Price

$5.50

Volume

21,594

Open

$5.83

Previous Close

$5.50

Daily Range

$5.47 - $5.83

52-Week Range

$2.43 - $10.99

LXEO News

Lexeo Reports Q2 Loss as Costs Jump 129%

Motley Fool Markets TeamAug 14, 2025

LXEO: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lexeo Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

R. Nolan Townsend, MBA

Website

www.lexeotx.com

Headquarters

New York City, 10010, US

LXEO Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-55%

Return on Capital

-41%

Return on Assets

-35%

Earnings Yield

-25.25%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$426.74M

Shares Outstanding

74.09M

Volume

21.59K

Avg. Volume

883.67K

Financials (TTM)

Gross Profit

$0.00

Operating Income

$109.26M

EBITDA

$97.68M

Operating Cash Flow

$98.56M

Capital Expenditure

$397.00K

Free Cash Flow

$98.96M

Cash & ST Invst.

$181.77M

Total Debt

$7.89M

Lexeo Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$546.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$426.74M

N/A

Market Cap/Employee

$5.69M

N/A

Employees

N/A

Net Income

$20.20M

+38.2%

EBITDA

$21.79M

+32.2%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$64.40M

-28.8%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$4.67M

-30.8%

Short Term Debt

$2.69M

+1.8%

Return on Assets

-34.95%

N/A

Return on Invested Capital

-41.41%

N/A

Free Cash Flow

$21.18M

+2.5%

Operating Cash Flow

$21.14M

+2.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

VNDAVanda Pharmaceuticals Inc.

VNDAVanda Pharmaceuticals Inc.$6.39-0.62%

KYTXKyverna Therapeutics, Inc.

KYTXKyverna Therapeutics, Inc.$10.74-0.37%

DBVTDBV Technologies S.A.

DBVTDBV Technologies S.A.$19.84+1.22%

SLNSilence Therapeutics plc

SLNSilence Therapeutics plc$7.13+2.15%

LRMRLarimar Therapeutics, Inc.

LRMRLarimar Therapeutics, Inc.$3.89-5.12%

CTNMContineum Therapeutics, Inc. Class A Common Stock

CTNMContineum Therapeutics, Inc. Class A Common Stock$14.21+0.42%

AMRNAmarin Corporation plc

AMRNAmarin Corporation plc$14.78-1.60%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

ONDSOndas

ONDSOndas$11.21+0.27%

FFord Motor Company

FFord Motor Company$14.48+0.07%

AIIORobo.ai

AIIORobo.ai$5.64+1.16%

NOKNokia

NOKNokia$14.46-0.02%

POETPoet Technologies

POETPoet Technologies$20.57+0.43%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$16.65-0.01%

AALAmerican Airlines Group

AALAmerican Airlines Group$12.70-0.00%

Questions About LXEO

What is the current price of Lexeo Therapeutics?

Lexeo Therapeutics is trading at $5.51 per share.

What is the 52-week range for Lexeo Therapeutics?

Over the past 52 weeks, Lexeo Therapeutics has traded between $2.43 and $10.99.

How much debt does Lexeo Therapeutics have?

As of the most recent reporting period, Lexeo Therapeutics reported total debt of $7.37M.

How much cash does Lexeo Therapeutics have on hand?

Lexeo Therapeutics reported $71.77M in cash and cash equivalents in its most recent financial results.

What is Lexeo Therapeutics’s dividend yield?

Lexeo Therapeutics does not currently have a dividend yield.

Lexeo Therapeutics

Lexeo Therapeutics Financials at a Glance

LXEO News

Lexeo Reports Q2 Loss as Costs Jump 129%

LXEO: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Lexeo Therapeutics

LXEO Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Lexeo Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About LXEO

What is the current price of Lexeo Therapeutics?

What is the 52-week range for Lexeo Therapeutics?

How much debt does Lexeo Therapeutics have?

How much cash does Lexeo Therapeutics have on hand?

What is Lexeo Therapeutics’s dividend yield?

Premium Investing Services